

Supplementary Table S1. Baseline characteristics of the male patients

Characteristics	Total (n = 527)	Survivor (n = 433)	Non-survivor (n = 94)	<i>p</i> -value
Age	67.0 (59.0–73.0)	67.0 (59.0–74.0)	65.0 (58.0–71.0)	0.12
Past illness				
HTN	175 (33.2)	144 (33.3)	31 (33.0)	0.96
DM	153 (28.8)	130 (30.0)	22 (23.4)	0.20
CAD	60 (11.4)	54 (12.5)	6 (6.4)	0.09
Pulmonary disease	41 (7.18)	30 (6.9)	11 (11.7)	0.12
Malignancy	222 (42.1)	177 (40.9)	45 (47.9)	0.21
Hematologic disorder	38 (7.2)	27 (6.2)	11 (11.7)	0.06
CKD	31 (5.9)	29 (6.7)	2 (2.1)	0.09
LC	100 (19.0)	76 (17.6)	24 (25.5)	0.07
Site of infection				
Unknown	49 (9.3)	39 (9.0)	10 (10.6)	0.62
Lung	100 (19.0)	77 (17.8)	23 (24.5)	0.13
Urinary tract	46 (8.7)	42 (9.7)	4 (4.3)	0.09
Intra-abdomen	82 (15.6)	59 (13.6)	23 (24.5)	<0.01
Hepato-biliary- pancreas	237 (45.0)	204 (47.1)	33 (35.1)	0.03
Blood stream	21 (4.0)	13 (3.0)	8 (8.5)	0.01
Lactate level	4.0 (2.0–6.0)	3.6 (1.9–5.5)	5.4 (2.7–9.2)	<0.01
SOFA score	7.0 (5.0–10.0)	7.0 (5.0–10.0)	9.0 (6.0–12.0)	<0.01
APACHE score	16.0 (11.0–20.0)	15.0 (11.0–19.0)	18.0 (14.0–22.8)	<0.01
Low SMI	328 (62.2)	268 (61.9)	60 (63.8)	0.73

Myosteatorsis	419 (79.5)	339 (78.3)	80 (85.1)	0.14
---------------	------------	------------	-----------	------

Data are presented as n (%) or median (interquartile range).

Abbreviations: HTN, hypertension; DM, diabetes mellitus; CAD, coronary artery disease; CKD, chronic kidney disease; LC, liver cirrhosis; SOFA, sequential organ failure assessment; APACHE, acute physiology and chronic health evaluation; SMI, skeletal muscle index.

Supplementary Table S2. Baseline characteristics of the female patients

Characteristics	Total (n = 369)	Survivor (n = 317)	Non-survivor (n = 52)	<i>p</i> -value
Age	67.0 (57.0–76.0)	68.0 (57.8–77.0)	65.5 (56.8–77.3)	0.62
Past illness				
HTN	124 (33.6)	109 (34.4)	15 (28.8)	0.43
DM	78 (21.1)	65 (20.5)	13 (25.0)	0.46
CAD	17 (4.6)	15 (4.7)	2 (3.8)	0.78
Pulmonary disease	6 (1.6)	4 (1.3)	2 (3.8)	0.17
Malignancy	155 (42.0)	126 (39.7)	29 (55.8)	0.03
Hematologic disorder	20 (5.4)	14 (4.4)	6 (11.5)	0.04
CKD	20 (5.4)	16 (5.0)	4 (7.7)	0.44
LC	39 (10.6)	32 (10.1)	7 (13.5)	0.46
Site of infection				
Unknown	33 (8.9)	28 (8.8)	5 (9.6)	0.86
Lung	47 (12.7)	35 (11.0)	12 (23.1)	0.02
Urinary tract	95 (25.7)	85 (26.8)	10 (19.2)	0.25
Intra-abdomen	59 (16.0)	49 (15.5)	10 (19.2)	0.49
Hepato-biliary- pancreas	121 (32.8)	107 (33.8)	14 (26.9)	0.33
Blood stream	18 (4.9)	13 (4.1)	5 (9.6)	0.09
Lactate level	3.0 (1.5–5.7)	2.8 (1.4–5.1)	5.9 (2.6–8.7)	<0.01
SOFA score	7.0 (5.0–9.0)	6.0 (5.0–8.0)	11.0 (6.0–14.0)	<0.01
APACHE score	15.0 (11.0–20.0)	14.0 (11.0–19.0)	20.5 (15.0–30.3)	<0.01
Low SMI	239 (64.8)	206 (65.0)	33 (63.5)	0.83

Myosteatorsis	313 (84.8)	268 (84.5)	45 (86.5)	0.71
---------------	------------	------------	-----------	------

Data are presented as n (%) or median (interquartile range).

Abbreviations: HTN, hypertension; DM, diabetes mellitus; CAD, coronary artery disease; CKD, chronic kidney disease; LC, liver cirrhosis; SOFA, sequential organ failure assessment; APACHE, acute physiology and chronic health evaluation; SMI, skeletal muscle index.

Supplementary Table S3. Baseline characteristics and body composition of patients with septic shock according to myosteatorsis

Characteristics	Total (n = 896)	Normal (n = 164)	Abnormal (n = 732)	<i>p</i> -value
Age	67.0 (58.0–75.0)	61.0 (55.0–67.0)	68.0 (60.0–76.0)	<0.01
Male	527 (58.8)	108 (65.9)	419 (57.2)	0.04
Past illness				
HTN	299 (33.4)	24 (14.6)	275 (37.6)	<0.01
DM	230 (25.7)	32 (19.5)	198 (27.0)	0.05
CAD	77 (8.6)	7 (4.3)	70 (9.6)	0.03
Chronic pulmonary disease	47 (5.2)	8 (4.9)	39 (5.3)	0.82
Malignancy	377 (42.1)	77 (47.0)	300 (41.0)	0.16
Hematologic disorder	58 (6.5)	11 (6.7)	47 (6.4)	0.89
CKD	51 (5.7)	7 (4.3)	44 (6.0)	0.38
LC	139 (15.5)	23 (14.0)	116 (15.8)	0.56
Site of infection				
Unknown	82 (9.2)	23 (14.0)	59 (8.1)	0.02
Lung	147 (16.4)	28 (17.1)	119 (16.3)	0.80
Urinary tract	141 (15.7)	16 (9.8)	125 (17.1)	0.02
Intra-abdomen	141 (15.7)	23 (14.0)	118 (16.1)	0.51
Hepato-biliary-pancreas	358 (40.0)	64 (39.0)	294 (40.2)	0.79
Blood stream	39 (4.4)	9 (5.5)	30 (4.1)	0.43
Lactate level	3.6 (1.9–5.8)	2.6 (1.5–5.3)	4.0 (1.9–6.0)	<0.01
SOFA score	7.0 (5.0–10.0)	6.0 (5.0–8.0)	7.0 (5.5–10.0)	<0.01

APACHE score	15.0 (11.0–20.0)	13.0 (10.0–17.0)	16.0 (12.0–20.0)	<0.01
BMI, kg/m ²	22.2 (19.7–24.6)	19.3 (17.5–21.1)	23.0 (20.7–25.4)	<0.01
SFA, cm ²	107.3 (65.7–157.0)	57.9 (27.1–87.5)	119.0 (81.6–164.3)	<0.01
VFA, cm ²	101.0 (57.4–158.9)	33.9 (17.3–64.2)	117.8 (78.7–171.9)	<0.01
SMA, cm ²	106.2 (90.6–125.6)	105.2 (92.5–124.4)	107.0 (91.6–126.6)	0.98
SMI, cm ² /m ²	40.6 (36.3–46.0)	39.8 (36.2–43.4)	41.0 (36.2–43.4)	0.11
Intramuscular adipose tissue area, cm ²	16.0 (9.6–23.2)	6.1 (3.9–8.6)	18.3 (13.6–25.6)	<0.01
Low attenuation MA, cm ²	49.2 (36.8–60.9)	28.0 (23.4–31.1)	53.5 (44.6–64.7)	<0.01
Normal attenuation MA, cm ²	56.8 (37.8–78.4)	80.4 (68.6–96.3)	51.4 (33.7–71.6)	<0.01
Total abdominal MA, cm ²	123.5 (109.2–142.1)	110.6 (96.0–129.8)	126.5 (112.5–146.0)	<0.01
Myosteotosis area, cm ²	66.6 (47.5–84.1)	35.0 (29.0–39.3)	72.8 (60.0–89.2)	<0.01
Myosteotosis percentage, %	53.3 (40.0–67.4)	29.2 (24.8–34.8)	58.1 (47.2–71.4)	<0.01

Data are presented as n (%) or median (interquartile range).

Abbreviations: HTN, hypertension; DM, diabetes mellitus; CAD, coronary artery disease; CKD, chronic kidney disease; LC, liver cirrhosis; SOFA, sequential organ failure assessment; APACHE, acute physiology and chronic health evaluation; BMI, body mass index; SFA, subcutaneous fat area; VFA, visceral fat area; SMA, skeletal muscle area; SMI, skeletal muscle index; MA, muscle area.